Cancer Epigenetics

Epigenetic changes are now recognized to be as important to cancer formation as are gene mutations. Unlike mutations, however, epigenetic states can be altered, and epigenetic therapies hold promise as anti-cancer agents. For these approaches to succeed, we must understand how epigenetic states are created and maintained, and how they are altered in particular malignancies. This meeting will highlight large scale epigenome mapping efforts in normal cells, stem cells, and cancer cells, as well as genetic and biochemical studies focused on defining the mechanistic underpinning of these states. The meeting will bring together basic scientists studying the enzymes that govern epigenetic marks, particularly DNA methylation and histone post translational modifications, with translational and clinical researchers who are developing and implementing new epigenetic therapies. Opportunities for cross fertilization of ideas and interdisciplinary interactions will be further strengthened by joint keynote and plenary sessions with the concurrent meeting on Transcriptional Regulation.
+ show speakers and program
Keynote Address (Joint)
C. David Allis, Rockefeller University, USA

Bing Ren, University of California, San Diego, USA
Systems Biology Approach to Defining Cancer Epigenomes

Dirk Schübeler, Friedrich Miescher Institute for Biomedical Research, Switzerland
Epigenetic Modification of Genome Function

Joan W. Conaway, Stowers Institute for Medical Research, USA
Transcription Initiation and Elongation

Patrick Cramer, University of Munich (LMU), Germany
The Transcription Apparatus

David H. Price, University of Iowa, USA
RNA Polymerase II Elongation Control

B. Franklin Pugh, Pennsylvania State University, USA
Genome-Wide Organization of Chromatin and the Transcription Machinery

Peter A. Jones, University of Southern California, USA
Targeting Chromatin for Therapy

Kornelia Polyak, Dana-Farber Cancer Institute, Harvard Medical School, USA
Chromatin Modifiers as Novel Therapeutic Targets in Breast Cancer

Peggy J. Farnham, University of Southern California, USA
Transcription Factor Profiles in Normal and Cancer Cells

Martha L. Bulyk, Harvard Medical School, USA
Transcription Factors and DNA Regulatory Elements

Robert G. Roeder, Rockefeller University, USA
Transcription and Cofactors

Robert A. Waterland, Baylor College of Medicine, USA
Nutritional Influences on Human Developmental Epigenetics

Sharon Y.R. Dent, University of Texas MD Anderson Cancer Center, USA
Functions of Gcn5 and SAGA in Stem Cells and Cancer

Yi Zhang, HHMI/Harvard Medical School, Children's Hospital Boston, USA
Chromatin Changes in Stem Cells and Cancer

Sung Hee Baek, Seoul National University, South Korea
Histone Modifiers in Epigenetic Control of Stem Cell Homeostasis and Cancer

Karen Adelman, NIEHS, National Institutes of Health, USA
RNA Polymerase Pausing during Early Murine Development

Margaret T. Fuller, Stanford University, USA
Transcriptional Regulation of Differentiation in an Adult Stem Cell Lineage

Michael S. Levine, University of California, Berkeley, USA
Pause Control in Development

Joanna Wysocka, Stanford University School of Medicine, USA
Mechanisms of Developmental Plasticity

Anjana Rao, La Jolla Institute for Allergy and Immunology, USA
5-Hydroxymethylcytosine in Development and Cancer

Craig B. Thompson, Memorial Sloan-Kettering Cancer Center, USA
Cellular Metabolism and Epigenetic Changes in Cancer

Megan P. Hitchins, Lowy Cancer Research Centre, University of New South Wales, Australia
Epimutations and Epialleles in Familial Cancers

Howard Y. Chang, Stanford University, USA
Long Non-Coding RNAs and Chromatin

John L. Rinn, Harvard University, USA
Biology of lincRNAs

Danny F. Reinberg, HHMI/New York University, USA
RNA and Chromatin Regulation

Jean-Pierre Issa, Temple University School of Medicine, USA
Unraveling the Epi Code in Aging and Cancer

Margaret A. Goodell, Baylor College of Medicine, USA
DNA Methylation in Normal and Malignant Hematopoiesis

Taiping Chen, University of Texas MD Anderson Cancer Center, USA
DNA Methyltransferases and Lysine Methyltransferases: Connections in Development and Disease

Leonard I. Zon, HHMI/Children's Hospital Boston, USA
Transcription Elongation in Blood Development and Cancer

Kenneth S. Zaret, University of Pennsylvania, USA
Regulatory Mechanisms in Mammalian Tissue Induction

Yali Dou, University of Michigan, USA
Molecular Function of the MLL Complex

Thomas G. Boyer, University of Texas Health Science Center at San Antonio, USA
Mediator in Disease

Mark T. Bedford, University of Texas MD Anderson Cancer Center, USA
Defining New Histone Reader Domains

James E. Bradner, Dana-Farber Cancer Institute, USA
Druggable Histone Reader Domains

Amanda G. Fisher, MRC Clinical Sciences Centre, UK
Epigenetic Mechanisms of Reprogramming

Richard A. Young, Whitehead Institute for Biomedical Research, USA
Control of Cell State

Stephen B. Baylin, Johns Hopkins University School of Medicine, USA
Role of Epigenetics in Cancer Treatments

Caretha L. Creasy, GlaxoSmithKline Pharmaceuticals, USA
Ezh2 Mutations in Lymphoma: New Therapeutic Strategies

Kenneth P. Nephew, Indiana University, USA
Epigenetic Therapies that Overcome Cancer Drug Resistance

Job Dekker, University of Massachusetts Medical School, USA
Long-Range Chromosomal Interactions

Michael Snyder, Stanford University School of Medicine, USA
Transcriptomes and Transcriptional Networks

4 Feb - 9 Feb 2014
Santa Fe
United States of America
meeting website